Review

February 28, 2024


Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
Jiaorong Qu, Le Wang, Yufei Li, et al.
Clin Mol Hepatol. 2024;30(3):303-325.

Review

April 26, 2024


Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Clin Mol Hepatol. 2024;30(3):326-344.

Original Article

March 12, 2024


Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, et al.
Clin Mol Hepatol. 2024;30(3):345-359.

Original Article

March 15, 2024


Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, et al.
Clin Mol Hepatol. 2024;30(3):360-374.

Original Article

March 26, 2024


Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, et al.
Clin Mol Hepatol. 2024;30(3):375-387.

Original Article

April 11, 2024


Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
Do Seon Song, Hee Yeon Kim, Young Kul Jung, et al.
Clin Mol Hepatol. 2024;30(3):388-405.

Original Article

April 11, 2024


Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, et al.
Clin Mol Hepatol. 2024;30(3):406-420.

Original Article

April 11, 2024


Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
Shuai Wang, Xiaohong Lin, Yunhua Tang, et al.
Clin Mol Hepatol. 2024;30(3):421-435.

Original Article

April 16, 2024


Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clin Mol Hepatol. 2024;30(3):436-448.

Original Article

April 16, 2024


Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, et al.
Clin Mol Hepatol. 2024;30(3):449-467.

Original Article

April 19, 2024


Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Clin Mol Hepatol. 2024;30(3):468-486.

Original Article

May 7, 2024


Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, et al.
Clin Mol Hepatol. 2024;30(3):487-499.

Original Article

May 10, 2024


Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, et al.
Clin Mol Hepatol. 2024;30(3):500-514.

Original Article

May 10, 2024


Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, et al.
Clin Mol Hepatol. 2024;30(3):515-538.

Original Article

May 14, 2024


Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, et al.
Clin Mol Hepatol. 2024;30(3):539-560.

Original Article

June 3, 2024


Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, et al.
Clin Mol Hepatol. 2024;30(3):561-576.


Articles in E-pub version are posted online ahead of regular printed publication.

Original Article
Non-Linear Association Between Liver Fibrosis Scores and Viral Load in Patients with Chronic Hepatitis B
Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim
Received April 12, 2024  Accepted July 18, 2024  
View: 102   Download: 13
Reply to Correspondence
Reply to correspondence regarding “Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV”
Cho-Rong Lee, Sung-Gyoo Park
Received July 16, 2024  Accepted July 17, 2024  
View: 80   Download: 5
Editorial
Reappraisal of Transarterial Radioembolization for Liver-Confined Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon
Received July 3, 2024  Accepted July 16, 2024  
View: 88   Download: 10
Reply to correspondence
Response to: Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era
Seren M. Gedallovich, Paul Y. Kwo
Received July 10, 2024  Accepted July 11, 2024  
View: 116   Download: 3
Review Article
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
Received April 28, 2024  Accepted July 10, 2024  
View: 269   Download: 29
Original Article
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Liu Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi
Received March 22, 2024  Accepted July 10, 2024  
View: 299   Download: 37
Correspondence
Correspondence on Editorial regarding “Class II Transactivator Restricts Viral Replication and Extends Its Effect to HBV”
Mehrangiz Dezhbord, Kyun-Hwan Kim
Received July 3, 2024  Accepted July 8, 2024  
View: 143   Download: 25
Editorial
Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Extrahepatic Cancer Risk: Is tenofovir better than entecavir?
Yewan Park, Dong Hyun Sinn
Received July 4, 2024  Accepted July 7, 2024  
View: 153   Download: 23
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind
Beom Kyung Kim
Received June 30, 2024  Accepted July 7, 2024  
View: 132   Download: 4
Correspondence
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid's mechanisms of action
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Received June 24, 2024  Accepted July 5, 2024  
View: 132   Download: 13
Correspondence on Editorial regarding“Macrophage ATG16L1: potential candidate for MASH treatment”
Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
Received June 24, 2024  Accepted July 5, 2024  
View: 160   Download: 13
Letter to the Editor
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Yixuan Zhu, Yee Hui Yeo, Xiaoyan Ma, Wenjing Ni, Junping Shi, Jie Li
Received June 3, 2024  Accepted July 3, 2024  
View: 203   Download: 21
Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy
Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip
Received April 18, 2024  Accepted July 4, 2024  
View: 158   Download: 17
Editorial
Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV
Cho-Rong Lee, Sung-Gyoo Park
Received June 20, 2024  Accepted July 3, 2024  
View: 194   Download: 31
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
Received June 25, 2024  Accepted June 29, 2024  
View: 259   Download: 15
Correspondence
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Received June 24, 2024  Accepted June 29, 2024  
View: 153   Download: 6
Review
Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li
Received April 3, 2024  Accepted June 26, 2024  
View: 263   Download: 48
Editorial
Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future
Antonio Bertoletti, Anthony T Tan
Received June 23, 2024  Accepted June 26, 2024  
View: 190   Download: 23
Review
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Received April 10, 2024  Accepted June 26, 2024  
View: 379   Download: 72
Original Article
UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL
Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian
Received April 7, 2024  Accepted June 24, 2024  
View: 355   Download: 76
Burden of Mortality from Hepatocellular Carcinoma and Biliary Tract Cancers by Race and Ethnicity and Sex in US, 2018-2023
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Received April 29, 2024  Accepted June 20, 2024  
View: 320   Download: 24
Correspondence
Correspondence on Editorial regarding “Dynamic Assessment of Modified Quick Sequential Organ Failure Assessment in Acutely Deteriorated Patients with Chronic Liver Disease”
Do Seon Song, Dong Joon Kim
Received June 12, 2024  Accepted June 14, 2024  
View: 432   Download: 5
Editorial
Macrophage ATG16L1: potential candidate for MASH treatment
Junjie Yu
Received June 11, 2024  Accepted June 14, 2024  
View: 332   Download: 24
Letter to the Editor
MAFLD-related hepatocellular carcinoma in China: An increasing problem
Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
Received May 22, 2024  Accepted June 17, 2024  
View: 405   Download: 27
Editorial
The impact of ischemia-free liver transplantation to improve the prognosis of recipients using functionally marginal liver grafts
Ho Joong Choi
Received June 4, 2024  Accepted June 6, 2024  
View: 293   Download: 15
Metformin and Statins and their role in reducing Hepatocellular Carcinoma Risk: Randomized trials are needed
Paul Y. Kwo
Received June 4, 2024  Accepted June 6, 2024  
View: 431   Download: 22
Meeting the challenges of HCC post SVR in the Post-DAA Era: A Path Forward
Seren M. Gedallovich, Paul Y. Kwo
Received June 3, 2024  Accepted June 6, 2024  
View: 373   Download: 11
Ursolic acid: A promising therapeutic agent for MASLD via inhibition of SPP1-induced Th17 cell differentiation
So Jung Kim, Jeongeun Hyun
Received May 31, 2024  Accepted June 6, 2024  
View: 590   Download: 30
Modified quick-SOFA score: can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?
Simone Incicco, Salvatore Piano
Received May 30, 2024  Accepted May 31, 2024  
View: 202   Download: 7
Correspondence
Correspondence on editorial regarding “Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Received May 24, 2024  Accepted May 29, 2024  
View: 385   Download: 25
Original Article
Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC
Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du
Received January 20, 2024  Accepted May 28, 2024  
View: 525   Download: 84
Editorial
MAFLD Is A Ubiquitous Latent Cofactor in Viral- and Alcoholic-related Hepatocellular Carcinoma
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Received May 18, 2024  Accepted May 20, 2024  
View: 432   Download: 28
Correspondence
Correspondence on Editorial regarding “Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: a gateway to personalized medicine”
Su Bin Lim, Hyo Jung Cho
Received May 16, 2024  Accepted May 19, 2024  
View: 366   Download: 21
Reply to Unlocking the future: machine learning sheds light on prognostication for early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Received May 16, 2024  Accepted May 19, 2024  
View: 338   Download: 11
Reply to Correspondence
Reply to correspondence: “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Received May 15, 2024  Accepted May 19, 2024  
View: 352   Download: 10
Letter to the Editor
Equivalent Prevalence and Progression of Chronic Kidney Disease in NAFLD and MASLD
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Received April 15, 2024  Accepted May 20, 2024  
View: 448   Download: 52
Correspondence
Correspondence on Editorial regarding “Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis”
Jiaorong Qu, Le Wang, Xiaojiaoyang Li
Received May 14, 2024  Accepted May 15, 2024  
View: 352   Download: 24
Editorial
Unveiling Etiology-Specific Blood Biomarkers in Hepatocellular Carcinoma: A Gateway to Personalized Medicine
Joseph C. Ahn, Ju Dong Yang
Received May 10, 2024  Accepted May 13, 2024  
View: 379   Download: 7
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure
Hae Lim Lee, Jeong Won Jang
Received May 9, 2024  Accepted May 13, 2024  
View: 256   Download: 21
Unlocking the Role of Liver Sinusoidal Endothelial Cells: Key Players in Liver Fibrosis
Yasuko Iwakiri
Received May 8, 2024  Accepted May 9, 2024  
View: 380   Download: 45
Letter to the Editor
Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi
Received April 7, 2024  Accepted May 10, 2024  
View: 388   Download: 30  Crossref: 1
Editorial
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma
Junlong Dai, Jimmy Che-To Lai, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
Received May 3, 2024  Accepted May 4, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0327    [Epub ahead of print]
View: 353   Download: 19
Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
Naoshi Nishida
Received May 2, 2024  Accepted May 3, 2024  
View: 343   Download: 43
Reply to Correspondence
Complement proteins and liver diseases: A response to the correspondence
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Received April 30, 2024  Accepted April 30, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0320    [Epub ahead of print]
View: 480   Download: 36
Correspondence
Reply to: “Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization”
Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
Received April 16, 2024  Accepted April 19, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0266    [Epub ahead of print]
View: 432   Download: 16
Reply to Correspondence
Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B”
Pin-Nan Cheng, Ming-Lung Yu
Received April 5, 2024  Accepted April 9, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0228    [Epub ahead of print]
View: 547   Download: 24
Snapshot
Examining the therapeutic landscape of beta-blockers in portal hypertension
Anna Brujats, Càndid Villanueva
Received February 24, 2024  Accepted March 4, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0144    [Epub ahead of print]
View: 1344   Download: 33

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 947
TOTAL : 1939082
Close layer